Details of the Drug

General Information of Drug (ID: DMH1M9B)

Drug Name

Benazepril

Synonyms

Benazapril; Benazeprilum; Benzazepril; Benazepril Sandoz; Benazeprilum [Latin]; Forteekor [veterinary]; Benazepril (INN); Benazepril Sandoz (TN); Benazepril [INN:BAN]; Forteekor [veterinary] (TN); Fortekor (TN); Lotensin (TN); CGS-14824-A; [(3S)-3-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-({(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
Malignant essential hypertension	BA00	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

424.5

Logarithm of the Partition Coefficient (xlogp)

1.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 79 % []
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.7 +/- 8.5 hours (prodrug benazepril), 22.3 +/- 9.2 hours (active metabolite benazeprilat), and 10 - 11 hours (accumulation) [4]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.13309 micromolar/kg/day [5]
Vd: The volume of distribution (Vd) of drug is 203 +/- 69.9 L []
Water Solubility: The ability of drug to dissolve in water is measured as 78 mg/mL [3]

Chemical Identifiers

Formula: C24H28N2O5
IUPAC Name: 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
Canonical SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O
InChI: InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
InChIKey: XPCFTKFZXHTYIP-PMACEKPBSA-N

Cross-matching ID

PubChem CID: 5362124
ChEBI ID: CHEBI:3011
CAS Number: 86541-75-5
DrugBank ID: DB00542
TTD ID: D0U3EC
VARIDT ID: DR00286
INTEDE ID: DR0186
ACDINA ID: D00060

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin-converting enzyme (ACE)	TTL69WB	ACE_HUMAN	Inhibitor	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 2 (SLC15A2)	DT8QKNP	S15A2_HUMAN	Substrate	[7]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Methylenetetrahydrofolate reductase (MTHFR)_{Main DME}	DEOXTPZ	MTHR_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Drug Response	[9]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Gene/Protein Processing	[10]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Drug Response	[11]
Cytochrome P450 11B2, mitochondrial (CYP11B2)	OTIOLWYN	C11B2_HUMAN	Drug Response	[12]
Lysosomal Pro-X carboxypeptidase (PRCP)	OTIUY91L	PCP_HUMAN	Drug Response	[13]
Matrix metalloproteinase-9 (MMP9)	OTB2QDAV	MMP9_HUMAN	Gene/Protein Processing	[14]
Methionine synthase (MTR)	OTF2K2TA	METH_HUMAN	Drug Response	[8]
Methylenetetrahydrofolate reductase (MTHFR)	OTUBJSR7	MTHR_HUMAN	Drug Response	[15]
Protein AMBP (AMBP)	OTLU8GU8	AMBP_HUMAN	Gene/Protein Processing	[16]
Renin (REN)	OT52GZR2	RENI_HUMAN	Gene/Protein Processing	[17]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Hypertension

ICD Disease Classification

BA00-BA04

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Angiotensin-converting enzyme (ACE)	DTT	SLC33A1	2.62E-01	-0.01	-0.06
Peptide transporter 1 (SLC15A1)	DTP	PEPT1	6.91E-01	8.30E-03	7.24E-02
Peptide transporter 2 (SLC15A2)	DTP	PEPT2	8.33E-02	-3.63E-02	-1.27E-01
Methylenetetrahydrofolate reductase (MTHFR)	DME	MTHFR	7.24E-01	3.19E-02	1.70E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Benazepril

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Eprosartan	DM07K2I	Major	Increased risk of hyperkalemia by the combination of Benazepril and Eprosartan.	Hypertension [BA00-BA04]	[18]
Aliskiren	DM1BV7W	Major	Increased risk of hyperkalemia by the combination of Benazepril and Aliskiren.	Hypertension [BA00-BA04]	[19]
Losartan	DM72JXH	Major	Increased risk of hyperkalemia by the combination of Benazepril and Losartan.	Hypertension [BA00-BA04]	[18]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Benazepril and Doxazosin.	Hypertension [BA00-BA04]	[20]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Benazepril and TAK-491.	Hypertension [BA00-BA04]	[18]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Benazepril and Indapamide.	Hypertension [BA00-BA04]	[21]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Benazepril and Trichlormethiazide.	Hypertension [BA00-BA04]	[21]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Benazepril and Telmisartan.	Hypertension [BA00-BA04]	[18]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Benazepril and Irbesartan.	Hypertension [BA00-BA04]	[18]
Hydrochlorothiazide	DMUSZHD	Moderate	Additive hypotensive effects by the combination of Benazepril and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[21]
-----------


⏷ Show the Full List of 10 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Benazepril (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[22]
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Benazepril due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[23]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Repaglinide.	Acute diabete complication [5A2Y]	[24]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Glibenclamide.	Acute diabete complication [5A2Y]	[24]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Tolazamide.	Acute diabete complication [5A2Y]	[24]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Nateglinide.	Acute diabete complication [5A2Y]	[24]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Insulin-glulisine.	Acute diabete complication [5A2Y]	[24]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Insulin-aspart.	Acute diabete complication [5A2Y]	[25]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Glipizide.	Acute diabete complication [5A2Y]	[24]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[26]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Benazepril and Linezolid.	Bacterial infection [1A00-1C4Z]	[27]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Benazepril and Cariprazine.	Bipolar disorder [6A60]	[28]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Benazepril and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[29]
Mannitol	DMSCDY9	Moderate	Additive hypotensive effects by the combination of Benazepril and Mannitol.	Bronchiectasis [CA24]	[21]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Benazepril and Drospirenone.	Contraceptive management [QA21]	[30]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Benazepril and Ardeparin.	Coronary thrombosis [BA43]	[18]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Benazepril and Selegiline.	Depression [6A70-6A7Z]	[27]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Benazepril and Isocarboxazid.	Depression [6A70-6A7Z]	[27]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Benazepril and Tranylcypromine.	Depression [6A70-6A7Z]	[27]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Benazepril and OPC-34712.	Depression [6A70-6A7Z]	[28]
SODIUM CITRATE	DMHPD2Y	Minor	Decreased absorption of Benazepril due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[23]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Cannabidiol.	Epileptic encephalopathy [8A62]	[31]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Benazepril and Ethacrynic acid.	Essential hypertension [BA00]	[32]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Benazepril and Phenoxybenzamine.	Essential hypertension [BA00]	[20]
Benzthiazide	DMQWZ0H	Moderate	Additive hypotensive effects by the combination of Benazepril and Benzthiazide.	Essential hypertension [BA00]	[21]
Acetazolamide	DM1AF5U	Moderate	Additive hypotensive effects by the combination of Benazepril and Acetazolamide.	Glaucoma [9C61]	[21]
Methazolamide	DM7J2TA	Moderate	Additive hypotensive effects by the combination of Benazepril and Methazolamide.	Glaucoma [9C61]	[21]
Dichlorphenamide	DMH7IDQ	Moderate	Additive hypotensive effects by the combination of Benazepril and Dichlorphenamide.	Glaucoma [9C61]	[32]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Benazepril and Eplerenone.	Heart failure [BD10-BD1Z]	[33]
Chlorothiazide	DMLHESP	Moderate	Additive hypotensive effects by the combination of Benazepril and Chlorothiazide.	Heart failure [BD10-BD1Z]	[21]
Furosemide	DMMQ8ZG	Moderate	Additive hypotensive effects by the combination of Benazepril and Furosemide.	Heart failure [BD10-BD1Z]	[21]
Amiloride	DMRTSGP	Major	Increased risk of hyperkalemia by the combination of Benazepril and Amiloride.	Heart failure [BD10-BD1Z]	[34]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Benazepril and Bumetanide.	Heart failure [BD10-BD1Z]	[21]
Hydroflumethiazide	DMVPUQI	Moderate	Additive hypotensive effects by the combination of Benazepril and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[21]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Benazepril and Procarbazine.	Hodgkin lymphoma [2B30]	[27]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[35]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Didanosine	DMI2QPE	Minor	Decreased absorption of Benazepril due to altered gastric pH caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Benazepril and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[37]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Benazepril and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[38]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Benazepril and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[39]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Benazepril and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[40]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Benazepril and Propiomazine.	Insomnia [7A00-7A0Z]	[28]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Benazepril and ITI-007.	Insomnia [7A00-7A0Z]	[28]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Methotrexate.	Leukaemia [2A60-2B33]	[31]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[41]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Clofarabine.	Mature B-cell lymphoma [2A85]	[42]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Benazepril due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[38]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Benazepril and Ozanimod.	Multiple sclerosis [8A40]	[27]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Benazepril and Promethazine.	Nausea/vomiting [MD90]	[28]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Benazepril and Polythiazide.	Oedema [MG29]	[21]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Benazepril and Safinamide.	Parkinsonism [8A00]	[27]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Benazepril and Rasagiline.	Parkinsonism [8A00]	[27]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Benazepril and Terazosin.	Prostate hyperplasia [GA90]	[20]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Benazepril and Silodosin.	Prostate hyperplasia [GA90]	[20]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Benazepril and Levomepromazine.	Psychotic disorder [6A20-6A25]	[28]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Benazepril and Fluphenazine.	Psychotic disorder [6A20-6A25]	[28]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Benazepril and Leflunomide.	Rheumatoid arthritis [FA20]	[38]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Benazepril and Quetiapine.	Schizophrenia [6A20]	[28]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Benazepril and Mesoridazine.	Schizophrenia [6A20]	[28]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Benazepril and Aripiprazole.	Schizophrenia [6A20]	[28]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Benazepril and Iloperidone.	Schizophrenia [6A20]	[28]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Benazepril and Paliperidone.	Schizophrenia [6A20]	[28]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Benazepril and Perphenazine.	Schizophrenia [6A20]	[28]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Benazepril and Molindone.	Schizophrenia [6A20]	[28]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Benazepril and Thiothixene.	Schizophrenia [6A20]	[28]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Benazepril and Trifluoperazine.	Schizophrenia [6A20]	[28]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Benazepril and Risperidone.	Schizophrenia [6A20]	[28]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Benazepril and Amisulpride.	Schizophrenia [6A20]	[28]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Benazepril and Asenapine.	Schizophrenia [6A20]	[28]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[31]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Benazepril and Naltrexone.	Substance abuse [6C40]	[43]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of hyperkalemia by the combination of Benazepril and Tacrolimus.	Transplant rejection [NE84]	[44]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[24]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[24]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[24]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Benazepril and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[24]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Benazepril and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[28]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Benazepril and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[45]
-----------


⏷ Show the Full List of 79 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Zinc stearate	E00209	11178	lubricant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Trihydroxystearin	E00317	25100	Emollient; Emulsifying agent; Solvent; Surfactant; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 31 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Benazepril 10 mg tablet	10 mg	Oral Tablet	Oral
Benazepril 20 mg tablet	20 mg	Oral Tablet	Oral
Benazepril 40 mg tablet	40 mg	Oral Tablet	Oral
Benazepril 5 mg tablet	5 mg	Oral Tablet	Oral
Benazepril Hydrochloride 5mg tablet	5mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6374).
2	Amlodipine FDA Label
3	BDDCS applied to over 900 drugs
4	The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV44-50; discussion IV51-5.
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
7	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
8	Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7.
9	Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors. J Hum Hypertens. 2016 Dec;30(12):766-771. doi: 10.1038/jhh.2016.24. Epub 2016 Apr 28.
10	Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant. 2008 Sep;23(9):2841-6. doi: 10.1093/ndt/gfn159. Epub 2008 Apr 5.
11	Beta2 adrenergic receptor gene Arg16Gly polymorphism is associated with therapeutic efficacy of benazepril on essential hypertension in Chinese. Clin Exp Hypertens. 2004 Aug;26(6):581-92. doi: 10.1081/ceh-200031839.
12	Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin Pharmacol Ther. 2006 Jun;79(6):581-9. doi: 10.1016/j.clpt.2006.02.007.
13	E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. Chin Med J (Engl). 2009 Oct 20;122(20):2461-5.
14	Expression of toll-like receptor 4, tumor necrosis factor- alpha, matrix metalloproteinase-9 and effects of benazepril in patients with acute coronary syndromes. Clin Med Insights Cardiol. 2010 Oct 11;4:89-93. doi: 10.4137/CMC.S5659.
15	A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study. Clin Exp Hypertens. 2005 Aug;27(6):509-21.
16	Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients. Scand J Urol Nephrol. 2005;39(6):511-7. doi: 10.1080/00365590510031264.
17	Sympathomoderating influence of benazepril in essential hypertension. J Hypertens. 1992 Apr;10(4):373-8. doi: 10.1097/00004872-199204000-00009.
18	Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
19	Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
20	Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
21	Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
22	Cerner Multum, Inc. "Australian Product Information.".
23	Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
24	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
25	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
26	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
27	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
28	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
29	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
30	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
31	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
32	Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
33	Product Information. Inspra (eplerenone). Searle, Chicago, IL.
34	Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
35	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
36	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
37	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
38	Canadian Pharmacists Association.
39	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
40	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
41	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
42	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
43	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
44	Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
45	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.